You need to sign in or sign up before continuing.
The New England journal of medicine
The most recent articles from:
N. Engl. J. Med.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
Type 1 diabetes mellitus is a T-cell-mediated autoimmune disease that leads to a major loss of insulin-secreting beta cells. The further decline of beta-cell function after clinical onset might be prevented by treatment with CD3 monoclonal antibodies, as suggested by the results of a phase 1 study. To provide proof of this therapeutic principle at the metabolic level, we initiated a phase 2 placebo-controlled trial with a humanized antibody, an aglycosylated human IgG1 antibody directed against CD3 (ChAglyCD3). ⋯ Short-term treatment with CD3 antibody preserves residual beta-cell function for at least 18 months in patients with recent-onset type 1 diabetes.